Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elamipretide for primary mitochondrial disease due to nuclear DNA mutations
ISRCTN92370847Phase 3Completed
- Sponsor
- Stealth BioTherapeutics
- Start
- Apr 2022
- Modality
- Peptides
01
Overview
Phase 3, randomised, double-blind trial in Mitochondriopathy comparing Elamipretide with Placebo (2 arms). Primary endpoint: 6-minute walk test distance. Started Apr 2022; status: completed.
02
Drugs
elamipretide
03
Conditions
Mitochondriopathy
Beyond the preview
Go deeper on ISRCTN92370847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN92370847.